Evidence map›Paper›PMID 31203481›Full record

ArticleNeurochemical research2019

JLX001 Modulated the Inflammatory Reaction and Oxidative Stress in pMCAO Rats via Inhibiting the TLR2/4-NF-κB Signaling Pathway.

Yanying Qiu, Qiyang Yin, Yuxiang Fei, Yize Li, Hongfei Huang, Weirong Fang, Weiyang Shen, Bingwen Liang, Xiong Zhu, Yunman Li

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. The effect of rosuvastatin on cardiogenic cerebral infarction.American journal of translational research · 2021
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yanying QiuState Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 24, Tongjia Alley, Gulou District, Nanjing, 210009, Jiangsu, China.
Qiyang YinState Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 24, Tongjia Alley, Gulou District, Nanjing, 210009, Jiangsu, China.
Yuxiang FeiState Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 24, Tongjia Alley, Gulou District, Nanjing, 210009, Jiangsu, China.
Yize LiSchool of Pharmacy, China Pharmaceutical University, No. 24, Tongjia Alley, Gulou District, Nanjing, 210009, Jiangsu, China.
Hongfei HuangSchool of Pharmacy, China Pharmaceutical University, No. 24, Tongjia Alley, Gulou District, Nanjing, 210009, Jiangsu, China.
Weirong FangState Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 24, Tongjia Alley, Gulou District, Nanjing, 210009, Jiangsu, China.
Weiyang ShenSchool of Science, China Pharmaceutical University, No. 24, Tongjia Alley, Gulou District, Nanjing, 210009, Jiangsu, China.
Bingwen LiangJiangsu Jinglixin Pharmaceutical Technology Company Limited, No. 18, Zhilan road, Jiangning University Town, Jiangning District, Nanjing, 211100, Jiangsu, China.
Xiong ZhuJiangsu Jinglixin Pharmaceutical Technology Company Limited, No. 18, Zhilan road, Jiangning University Town, Jiangning District, Nanjing, 211100, Jiangsu, China. cpuzx@foxmail.com.
Yunman LiState Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 24, Tongjia Alley, Gulou District, Nanjing, 210009, Jiangsu, China. yunmanlicpu@163.com.ORCID http://orcid.org/0000-0001-5565-3322

Funding

National Major Scientific and Technological Special Project for "Significant New Drugs Development" during the Thirteenth Five-year Plan Period 2016ZX09101031National Major Scientific and Technological Special Project for "Significant New Drugs Development" during the Thirteenth Five-year Plan Period 2018ZX09301043-00The "Double First-Class" Construction Technology Innovation Team Project of China Pharmaceutical University CPU2018GY23
6 · The paper itself

Abstract

Inflammatory reactions and oxidative stress play critical roles in cerebral ischemic injuries. Microglia are activated after ischemic injury. Activated microglia produce neurotoxic proinflammatory factors and reactive oxygen species (ROS), which have been demonstrated closely related TLR2/4-NF-κB signal pathways. This study was to evaluate the effect of JLX001 against ischemic injury and investigate the mechanisms. The permanent middle cerebral artery occlusion (pMCAO) model was employed in rats. The neurobehavioral score, brain infarction rate, brain water content, pathological changes, immunohistochemical staining, biochemical index (T-AOC, SOD, and MDA), proinflammatory factors (IL-1β, TNF-α, and NO), expression of TLR2/4 and nuclear translocation of NF-κB p65 were determined. To explore probable underlying mechanism of the neuroprotective effect of JLX001, BV-2 cells were exposed to in oxygen-glucose deprivation (OGD) for 4 h to mimic ischemic injury in vitro. The result showed that JLX001 significantly decreased neurological deficit score, infarct size, and brain edema, attenuated pathological changes, inhibited the activation of microglia, improved the process of oxidative stress, reduced the release of proinflammatory cytokines and downregulated TLR2/4-NF-κB signal pathway. Moreover, OGD reduced BV2 cell viability, induced oxidative damage, increased the release of proinflammatory factors and activated TLR2/4-NF-κB signal pathway, which was significantly reversed by the intervention of JLX001. This study demonstrates that JLX001 is effective in protecting the brain from ischemic injury, which may be mediated by regulating oxidative stress, inflammation and inhibiting TLR2/4-NFκB signal pathway.

Indexed as

AnimalsCell HypoxiaCell LineDentate GyrusInfarction, Middle Cerebral ArteryInflammationMaleMiceNeuroprotective AgentsNF-kappa BOxidative StressRats, Sprague-DawleySignal TransductionToll-Like Receptor 2Toll-Like Receptor 4TriterpenesJLX001Neuroprotective AgentsNF-kappa BTlr2 protein, ratTlr4 protein, ratToll-Like Receptor 2Toll-Like Receptor 4TriterpenesCyclovirobuxine DMicrogliaOxidative stressPermanent cerebral ischemiaTLR2/4-NF-κB

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.